Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell securities tied to NBIX holdings. The filing lists 40,000 previously vested RSUs/PSUs with an original date of 02/01/2020 and 205,088 shares from an exercise of stock options on 05/19/2026.
The filing shows transaction type labels including Previously Vested RSUs & PSUs and Exercise of Stock Options, and identifies NASDAQ as the market. Cash treatment is noted for the option exercise.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions. The weighted average sale price was $157.6507 per share, with individual trades ranging from $155.51 to $158.68. These sales were executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026. Following the transactions, Pops directly holds 34,480 shares of Neurocrine common stock. The options exercised were granted on May 20, 2016 and are scheduled to expire on May 20, 2026.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions. The weighted average sale price was $157.6507 per share, with individual trades ranging from $155.51 to $158.68. These sales were executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026. Following the transactions, Pops directly holds 34,480 shares of Neurocrine common stock. The options exercised were granted on May 20, 2016 and are scheduled to expire on May 20, 2026.
Neurocrine Biosciences completed its all-cash acquisition of Soleno Therapeutics for approximately $2.9 billion. The deal was executed via a tender offer at $53.00 per Soleno share, followed by a short-form merger that makes Soleno a wholly owned subsidiary.
As of the offer expiration, 46,356,114 Soleno shares had been validly tendered, representing 88.9% of Soleno’s outstanding stock. The acquisition adds VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s commercial portfolio alongside INGREZZA and CRENESSITY.
On May 14, 2026, Neurocrine also entered into a five-year senior secured revolving credit facility of $1.0 billion and made an initial borrowing of $600.0 million under this facility, which is secured by substantially all of the company’s and certain subsidiaries’ assets.
Neurocrine Biosciences completed its all-cash acquisition of Soleno Therapeutics for approximately $2.9 billion. The deal was executed via a tender offer at $53.00 per Soleno share, followed by a short-form merger that makes Soleno a wholly owned subsidiary.
As of the offer expiration, 46,356,114 Soleno shares had been validly tendered, representing 88.9% of Soleno’s outstanding stock. The acquisition adds VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s commercial portfolio alongside INGREZZA and CRENESSITY.
On May 14, 2026, Neurocrine also entered into a five-year senior secured revolving credit facility of $1.0 billion and made an initial borrowing of $600.0 million under this facility, which is secured by substantially all of the company’s and certain subsidiaries’ assets.
Neurocrine Biosciences completed the acquisition of Soleno Therapeutics through a tender offer and subsequent merger. The Purchaser accepted for payment 46,356,114 Shares that were validly tendered, representing approximately 88.9% of outstanding Soleno common stock as of the offer Expiration Time. Purchaser accepted tenders on May 17, 2026 at an offer price of $53.00 per Share. Following acceptance, Purchaser merged into Soleno under Section 251(h) of the DGCL, with Soleno surviving as a wholly owned subsidiary of Neurocrine. Neurocrine and Purchaser intend to delist the Shares from Nasdaq and seek termination of registration and suspension of Soleno’s reporting obligations.
Neurocrine Biosciences completed the acquisition of Soleno Therapeutics through a tender offer and subsequent merger. The Purchaser accepted for payment 46,356,114 Shares that were validly tendered, representing approximately 88.9% of outstanding Soleno common stock as of the offer Expiration Time. Purchaser accepted tenders on May 17, 2026 at an offer price of $53.00 per Share. Following acceptance, Purchaser merged into Soleno under Section 251(h) of the DGCL, with Soleno surviving as a wholly owned subsidiary of Neurocrine. Neurocrine and Purchaser intend to delist the Shares from Nasdaq and seek termination of registration and suspension of Soleno’s reporting obligations.
Neurocrine Biosciences completed the acquisition of Soleno Therapeutics through a tender offer and subsequent merger. The Purchaser accepted for payment 46,356,114 Shares that were validly tendered, representing approximately 88.9% of outstanding Soleno common stock as of the offer Expiration Time. Purchaser accepted tenders on May 17, 2026 at an offer price of $53.00 per Share. Following acceptance, Purchaser merged into Soleno under Section 251(h) of the DGCL, with Soleno surviving as a wholly owned subsidiary of Neurocrine. Neurocrine and Purchaser intend to delist the Shares from Nasdaq and seek termination of registration and suspension of Soleno’s reporting obligations.
Neurocrine Biosciences completed the acquisition of Soleno Therapeutics through a tender offer and subsequent merger. The Purchaser accepted for payment 46,356,114 Shares that were validly tendered, representing approximately 88.9% of outstanding Soleno common stock as of the offer Expiration Time. Purchaser accepted tenders on May 17, 2026 at an offer price of $53.00 per Share. Following acceptance, Purchaser merged into Soleno under Section 251(h) of the DGCL, with Soleno surviving as a wholly owned subsidiary of Neurocrine. Neurocrine and Purchaser intend to delist the Shares from Nasdaq and seek termination of registration and suspension of Soleno’s reporting obligations.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk sold 3,810 shares of common stock in an open-market transaction at a weighted average price of $155.0134 per share. The trades were executed by a broker at prices ranging from $155.00 to $155.0550.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which was adopted and made effective in advance and cannot be modified under issuer policy after adoption. Following this transaction, Norwalk directly holds 2,429 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences reported sharply stronger Q1 2026 results, with net income of $197.9 million and diluted EPS of $1.91, up from $0.08 a year earlier.
Total revenues rose to $814.5 million from $572.6 million, driven by INGREZZA net product sales of $656.9 million and CRENESSITY net product sales of $153.3 million as demand and new prescriptions grew. Operating income increased to $193.4 million, helped by a $28.6 million gain on the sale of Neurocrine Group Limited and higher investment and equity gains.
Neurocrine ended the quarter with $2.65 billion in cash, cash equivalents and marketable securities and generated $145.8 million of operating cash flow, while repurchasing $56.0 million of stock. The company agreed to acquire Soleno Therapeutics for approximately $2.9 billion in cash and expects to fund the deal with cash and investments, which will significantly reduce its cash balances.
Neurocrine Biosciences reported sharply stronger Q1 2026 results, with net income of $197.9 million and diluted EPS of $1.91, up from $0.08 a year earlier.
Total revenues rose to $814.5 million from $572.6 million, driven by INGREZZA net product sales of $656.9 million and CRENESSITY net product sales of $153.3 million as demand and new prescriptions grew. Operating income increased to $193.4 million, helped by a $28.6 million gain on the sale of Neurocrine Group Limited and higher investment and equity gains.
Neurocrine ended the quarter with $2.65 billion in cash, cash equivalents and marketable securities and generated $145.8 million of operating cash flow, while repurchasing $56.0 million of stock. The company agreed to acquire Soleno Therapeutics for approximately $2.9 billion in cash and expects to fund the deal with cash and investments, which will significantly reduce its cash balances.
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 5,257,941 shares of Neurocrine Biosciences common stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard Capital Management LLC and specified Vanguard affiliates exercise dispositive power over these shares and that holdings include securities held for Vanguard funds and managed clients. The statement is signed by Ashley Grim, Head of Global Fund Administration, on 04/30/2026.